Marquette Asset Management’s ResMed RMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.36K Buy
+7
New +$1.45K ﹤0.01% 687
2026
Q1
Sell
-30
Closed -$7.23K 891
2025
Q4
$7.23K Buy
30
+8
+36% +$2.05K ﹤0.01% 267
2025
Q3
$6.02K Buy
+22
New +$6.01K ﹤0.01% 302
2023
Q3
Sell
-628
Closed -$137K 305
2023
Q2
$137K Hold
628
0.03% 96
2023
Q1
$138K Hold
628
0.04% 97
2022
Q4
$131K Hold
628
0.04% 96
2022
Q3
$137K Hold
628
0.04% 82
2022
Q2
$132K Hold
628
0.04% 106
2022
Q1
$152K Hold
628
0.04% 114
2021
Q4
$164K Hold
628
0.03% 114
2021
Q3
$166K Hold
628
0.04% 114
2021
Q2
$155K Hold
628
0.03% 109
2021
Q1
$122K Hold
628
0.03% 117
2020
Q4
$133K Hold
628
0.03% 112
2020
Q3
$108K Hold
628
0.03% 101
2020
Q2
$121K Hold
628
0.04% 100
2020
Q1
$92K Hold
628
0.04% 107
2019
Q4
$97K Hold
628
0.03% 101
2019
Q3
$85K Hold
628
0.03% 114
2019
Q2
$77K Hold
628
0.03% 124
2019
Q1
$65K Buy
+628
New +$64.8K 0.02% 135

Other funds holding RMD

Marquette Asset Management's RMD Position: Q2 2026 in Review

Marquette Asset Management opened a new position in ResMed (RMD) in Q2 2026: 7 shares worth $1.36K. The stake represents ﹤0.01% of the portfolio and ranks #687 among its holdings. This is a return to the name: Marquette Asset Management previously reported a position in RMD as recently as Q4 2025.

Marquette Asset Management first reported a position in RMD in Q1 2019 and has held it in 21 quarters since. The position peaked at $166K in Q3 2021. 319 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

  • Marquette Asset Management held 7 shares of ResMed worth $1.36K as of Q2 2026.
  • ResMed was a new Marquette Asset Management position in Q2 2026.
  • ResMed made up ﹤0.01% of Marquette Asset Management's portfolio in Q2 2026, its #687 holding.
  • Marquette Asset Management first reported a position in ResMed in Q1 2019 and has held it in 21 quarters since.
  • Marquette Asset Management's ResMed position peaked at $166K in Q3 2021.
  • 319 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Marquette Asset Management's 13F filing for Q2 2026, filed 9 Jul 2026.